Compare Amphastar Pharmaceuticals Inc (AMPH) vs Manchester United PLC (MANU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Manchester United PLC — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Manchester United PLC trades at $22.23 (market cap $3.74B). The key difference: Manchester United PLC is far larger — about 4.3× Amphastar Pharmaceuticals Inc's market cap, and Manchester United PLC pays a 1.26% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | MANU | |
|---|---|---|
Market Cap | $863.95M | $3.74B |
Sector | Health | Media |
52-Week High | $30.81 | $23.53 |
52-Week Low | $16.87 | $15.10 |
Enterprise Value | $1.26B | $4.68B |
Dividend Yield | — | 1.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Manchester United (MANU) trades at $21.63, down 1.28% on the day, with a bearish technical signal and negative profitability metrics including a net income margin of -2.65% and ROE of -6.36%. Recent news highlights stadium development progress and Champions League qualification, but revenue growth remains limited. Cash flow trends show volatile investing activities, with 2025 net cash flow at $12.56 million.
The outlook is mixed: analyst consensus leans Hold (60%) with potential from cost reductions and stadium plans, but persistent losses and high debt pose risks. Near-term catalysts include Q2 2026 earnings, yet structural challenges in revenue expansion and weak cash conversion temper upside potential for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Manchester United PLC
Manchester United PLC operates a professional football club together with related and ancillary activities. The company manages the soccer team and all affiliated club activities of the Manchester United Football Club, which includes the media network, foundation, fan zone, news, sports features, and team merchandise. Manchester United is based in England. The company has three principal sectors from which most of the revenue is generated, including Commercial, Broadcasting, and Matchday.
Read more on MANU →
